zacks.comNov 5$BDX

BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat

Becton, Dickinson and Company (BDX) reported Q4 fiscal 2026 adjusted EPS of $4.15, up 27.3% YoY, and revenue of $5.27B, up 5.4% YoY, both exceeding estimates. All segments and regions showed growth, with Interventional leading. Despite strong results, BDX shares fell 6.4% in pre-market trading due to low-single-digit revenue growth guidance for fiscal 2027.

Original reporting

zacks.com

Published Nov 5, 2026, 5:12 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 6:05 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat — source image — Source · zacks.com

Decision brief

The 30-second read

$BDXBearishHigh

Why it matters

The mixed news triggered a 6.4% pre‑market decline, highlighting investor sensitivity to guidance despite strong quarterly performance.

Market read

Earnings beat with weak guidance creates short‑term downside risk for BDX and may influence sentiment across the med‑tech sector.

What to watch

The $19B U.S. manufacturing investment and new product launches may provide longer‑term upside not reflected in the immediate price move.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Becton, Dickinson and Company (BDX) reported Q4 FY2026 results, beating estimates on earnings and revenue, but issued modest FY2027 guidance and announced a $19B U.S. investment plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BDXBearishHigh confidence

Context

Q4 2026 earnings beat and guidance release; adjusted EPS $4.15 beat estimate, revenue $5.27B beat, but guidance shows low‑single‑digit revenue growth, causing 6.4% pre‑market decline.

Expected impact

likely further downside as investors price in slower FY2027 revenue growth.

Evidence & confidence

Strong Q4 results are positive, but guidance and pre‑market sell‑off indicate market will stay bearish until guidance is clarified.

Market effects

Sector

Medical device sector may see pressure as BDX signals slower growth, prompting peers to reassess guidance.

Regional

U.S. healthcare stocks could face short‑term weakness.

Global

Limited; impact confined to U.S. med‑tech investors.

Counterpoint

What could challenge this read

The earnings beat and margin expansion could support a bounce if investors focus on operational strength over guidance.

Key entities

company
Becton, Dickinson and Company
Medical technology firm reporting Q4 earnings and FY2027 guidance.
government
U.S. Government
Partnered with BDX for domestic manufacturing investment.

Read at source ← All news

$BDXMed

Wells Fargo upgrades Becton Dickinson to Overweight from Equal-Weight, raises price target to $242 from $170

Wells Fargo upgraded Becton Dickinson to Overweight, raising its price target to $242 from $170, suggesting a 13.3% upside from the Nov 5 close of $213.55.

tradingview.comNov 6

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

finance.yahoo.comNov 6

$BDXMed

Wells Fargo upgrades Becton Dickinson stock rating on execution

Wells Fargo upgraded Becton Dickinson (BDX) to Overweight, raising its price target to $242. The company reported strong Q4 results, with revenue of $5.3B and EPS of $4.15, exceeding estimates. BDX has shown improved execution and conservative guidance for FY2027, with sales growth of 5.6% in Q4.

investing.comNov 6

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.

finance.yahoo.comNov 6

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 2026 Earnings Call Summary

Becton, Dickinson (BD) reported Q4 2026 earnings, highlighting 27.3% adjusted EPS growth driven by revenue gains and cost savings. The company completed a life sciences spin-off, focusing on medtech. BD expects fiscal 2027 revenue growth of mid-single digits, with Q1 performance at the low end due to Alaris headwinds. Operating margins are projected to be flat. Management targets 90% free cash flow conversion and plans to return $3.6 billion to shareholders.

finance.yahoo.comNov 5

$BDXHigh

Jefferies raises Becton Dickinson stock price target on guidance

Jefferies raised its price target on Becton Dickinson (BDX) to $242 from $210, citing strong Q4 results and guidance. BDX reported $5.27B in sales, up 5.6%, and EPS of $4.15, up 27%. The company projected fiscal 2027 sales growth of low single digits and EPS of $13.10-$13.30. Jefferies views the guidance as conservative and sees potential upside. BDX stock has surged 55% over the past year.

investing.comNov 5